AU2005267932A1 - Piperidine derivatives as histamine H3 receptor ligands - Google Patents

Piperidine derivatives as histamine H3 receptor ligands Download PDF

Info

Publication number
AU2005267932A1
AU2005267932A1 AU2005267932A AU2005267932A AU2005267932A1 AU 2005267932 A1 AU2005267932 A1 AU 2005267932A1 AU 2005267932 A AU2005267932 A AU 2005267932A AU 2005267932 A AU2005267932 A AU 2005267932A AU 2005267932 A1 AU2005267932 A1 AU 2005267932A1
Authority
AU
Australia
Prior art keywords
benzo
dihydro
pct
phenyl
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005267932A
Other languages
English (en)
Inventor
James Folmer
Peter Hamley
Simon Fraser Hunt
Steven Wesolowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of AU2005267932A1 publication Critical patent/AU2005267932A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2005267932A 2004-08-02 2005-07-27 Piperidine derivatives as histamine H3 receptor ligands Abandoned AU2005267932A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0401971-7 2004-08-02
SE0401971A SE0401971D0 (sv) 2004-08-02 2004-08-02 Piperidne derivatives
PCT/SE2005/001189 WO2006014136A1 (en) 2004-08-02 2005-07-27 Piperidine derivatives as histamine h3 receptor ligands

Publications (1)

Publication Number Publication Date
AU2005267932A1 true AU2005267932A1 (en) 2006-02-09

Family

ID=32906883

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005267932A Abandoned AU2005267932A1 (en) 2004-08-02 2005-07-27 Piperidine derivatives as histamine H3 receptor ligands

Country Status (14)

Country Link
US (1) US20080064706A1 (OSRAM)
EP (1) EP1781613A1 (OSRAM)
JP (1) JP2008508353A (OSRAM)
KR (1) KR20070043998A (OSRAM)
CN (1) CN1993325A (OSRAM)
AU (1) AU2005267932A1 (OSRAM)
BR (1) BRPI0514035A (OSRAM)
CA (1) CA2576112A1 (OSRAM)
IL (1) IL180548A0 (OSRAM)
MX (1) MX2007001226A (OSRAM)
RU (1) RU2007105970A (OSRAM)
SE (1) SE0401971D0 (OSRAM)
WO (1) WO2006014136A1 (OSRAM)
ZA (1) ZA200700683B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1608319A4 (en) 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
EP1814875A4 (en) 2004-10-20 2010-02-17 Univ California IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE
EP1836179B1 (en) 2004-12-30 2015-05-06 Janssen Pharmaceutica NV Piperidine- and piperazine-1-carboxylic acid amide derivatives and related compounds as modulators of fatty acid amide hydrolase (faah) for the treatment of anxiety, pain and other conditions
AU2006275568A1 (en) 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
MX2009013865A (es) * 2007-06-22 2010-01-27 Hoffmann La Roche Urea y derivados carbamato como inhibidores no nucleosidicos de la transcriptasa inversa.
MX2010005225A (es) 2007-11-13 2010-05-27 Taisho Pharmaceutical Co Ltd Derivados de fenilpirazol.
US8598356B2 (en) 2008-11-25 2013-12-03 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
US8461159B2 (en) 2008-11-25 2013-06-11 Jannsen Pharmaceutica BV Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
TW201039822A (en) 2009-02-06 2010-11-16 Taisho Pharmaceutical Co Ltd Dihydroquinolinone derivatives
PT3252057T (pt) 2009-12-04 2024-06-04 Sunovion Pharmaceuticals Inc Compostos multicíclicos e métodos de utilização dos mesmos
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
UA108233C2 (uk) 2010-05-03 2015-04-10 Модулятори активності гідролази амідів жирних кислот
US9045445B2 (en) 2010-06-04 2015-06-02 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012113103A1 (en) * 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
TW201321353A (zh) 2011-10-08 2013-06-01 Novartis Ag 胺基甲酸酯/尿素衍生物
JP6098892B2 (ja) 2011-12-08 2017-03-22 大正製薬株式会社 フェニルピロール誘導体
WO2013100054A1 (ja) 2011-12-27 2013-07-04 大正製薬株式会社 フェニルトリアゾール誘導体
US9034874B2 (en) 2012-07-20 2015-05-19 Novartis Ag Carbamate/urea derivatives
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途
MX375153B (es) 2014-05-19 2025-03-06 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelminticos.
EP3383853B1 (en) 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
CA3017048C (en) 2016-03-22 2023-11-07 Helsinn Healthcare Sa Benzenesulfonyl-asymmetric ureas and medical uses thereof
US10774064B2 (en) 2016-06-02 2020-09-15 Cadent Therapeutics, Inc. Potassium channel modulators
MX2019000982A (es) 2016-07-29 2019-07-04 Sunovion Pharmaceuticals Inc Compuestos y composiciones y usos de los mismos.
EA201990400A1 (ru) 2016-07-29 2019-07-31 Суновион Фармасьютикалз, Инк. Соединения и композиции и их применение
BR112019014814B1 (pt) 2017-01-23 2024-03-12 Novartis Ag Compostos, composições farmacêuticas dos mesmos e seus usos no tratamento de doenças associadas à disfunção de canais iônicos de potássio
CN116808023A (zh) 2017-02-16 2023-09-29 桑诺维恩药品公司 治疗精神分裂症的方法
JP7191085B2 (ja) 2017-08-02 2022-12-16 サノビオン ファーマシューティカルズ インク イソクロマン化合物およびその使用
MX2020008537A (es) 2018-02-16 2021-01-08 Sunovion Pharmaceuticals Inc Sales, formas cristalinas y metodos de produccion de las mismas.
SG11202009438UA (en) 2018-04-18 2020-11-27 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
CN112262143A (zh) 2018-05-21 2021-01-22 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
AU2019366312B2 (en) 2018-10-22 2025-04-24 Novartis Ag Crystalline forms of potassium channel modulators
CN111349609A (zh) * 2018-12-21 2020-06-30 泰州医药城国科化物生物医药科技有限公司 一种无标记组胺受体h3的细胞筛选模型
CN113784755B (zh) 2019-03-14 2024-05-10 赛诺维信制药公司 异色满基化合物的盐及其结晶形式、制备方法、治疗用途和药物组合物
EP3969444A4 (en) * 2019-05-13 2023-10-18 The Regents of the University of California COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES AND DISORDERS
PH12022550188A1 (en) 2019-07-24 2022-11-21 Constellation Pharmaceuticals Inc Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
ES2819309B2 (es) * 2019-10-14 2021-11-17 Fundacion Para La Investigacion Biomedica Del Hospital Univ De La Princesa Compuestos agonistas nicotínicos y antioxidantes para el tratamiento de enfermedades neurodegenerativas
CA3180115A1 (en) 2020-04-14 2021-10-21 Sunovion Pharmaceuticals Inc. (s)-(4,5-dihydro-7h-thieno[2,3-c]pyran-7-yl)-n-methylmethanamine for treating neurological and psychiatric disorders
CN113549006B (zh) * 2020-04-26 2023-07-21 江苏恩华药业股份有限公司 一种酰胺衍生物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
DE19614204A1 (de) * 1996-04-10 1997-10-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE450508T1 (de) * 2001-09-14 2009-12-15 High Point Pharmaceuticals Llc Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
US6673829B2 (en) * 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1554260A1 (en) * 2002-10-22 2005-07-20 Glaxo Group Limited Aryloxyalkylamine derivatives as h3 receptor ligands
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
JP4765627B2 (ja) * 2003-09-22 2011-09-07 Msd株式会社 新規ピペリジン誘導体

Also Published As

Publication number Publication date
BRPI0514035A (pt) 2008-05-27
WO2006014136A1 (en) 2006-02-09
KR20070043998A (ko) 2007-04-26
SE0401971D0 (sv) 2004-08-02
ZA200700683B (en) 2008-08-27
RU2007105970A (ru) 2008-09-10
CA2576112A1 (en) 2006-02-09
IL180548A0 (en) 2007-06-03
US20080064706A1 (en) 2008-03-13
EP1781613A1 (en) 2007-05-09
MX2007001226A (es) 2007-03-23
JP2008508353A (ja) 2008-03-21
CN1993325A (zh) 2007-07-04

Similar Documents

Publication Publication Date Title
US20080064706A1 (en) Piperidine Derivatives as Histamine H3 Receptor Ligands
US20070249618A1 (en) Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression
US20090111865A1 (en) Benzimidazole Derivatives, Compositions Containing Them, Preparation Thereof and Uses Thereof
AU2005267930A1 (en) Novel piperidine derivative for the treatment of depression
US7384955B2 (en) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
US20080004288A1 (en) Indazole Sulphonamide Derivatives
AU2005247835A1 (en) Therapeutic compounds
US7407968B2 (en) Compounds
US7517898B2 (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1458684B1 (en) Therapeutic heterocycles as bradykinin b2 receptor antagonists
ZA200503553B (en) 4(Pheny-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders
US20070265325A1 (en) Nitro Indazole Derivatives
HK1068348B (en) Therapeutic heterocycles as bradykinin b2 receptor antagonists

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted